Aurinia Pharmaceuticals Inc. (AUPH) Deep Dive Video

Summary

Aurinia combines a profitable, high-margin lupus nephritis franchise with underappreciated autoimmune pipeline optionality, creating an asymmetric value setup if patent defenses hold and clinical catalysts mature.

View AUPH stock page · Read the AUPH research report

Loading the video player…